140 results on '"Isacchi, Antonella"'
Search Results
2. Mining potentially actionable kinase gene fusions in cancer cell lines with the KuNG FU database
3. Abstract CT025: NMS-03592088, a novel, potent FLT3, KIT and CSF1R inhibitor with activity in FLT3 positive acute myeloid leukemia patients with prior FLT3 inhibitor experience
4. Abstract 1615: NMS-812, a novel potent PERK inhibitor that also inhibits GCN2, exhibits strong anti-tumor activity as single agent and in combination in preclinical models
5. Abstract 4036: NMS-0963 is a novel potent, selective and orally available Syk inhibitor with promising preclinical activity in diffuse large B-cell lymphoma
6. Comprehensive kinome NGS targeted expression profiling by KING-REX
7. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition
8. Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
9. Discovery of drug mode of action and drug repositioning from transcriptional responses
10. Identification of Myb-binding Protein 1A (MYBBP1A) as a Novel Substrate for Aurora B Kinase
11. A Six-Amino Acid Deletion in Basic Fibroblast Growth Factor Dissociates its Mitogenic Activity from its Plasminogen Activator-Inducing Capacity
12. A new approach to phosphoserine and phosphothreonine analysis in peptides and proteins: chemical modification, enrichment via solid-phase reversible binding, and analysis by mass spectrometry
13. Cross platform microarray analysis for robust identification of differentially expressed genes
14. A benchmarking of pipelines for detecting ncRNAs from RNA-Seq data
15. A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML
16. Molecular Dynamics Simulations of p97 Including Covalent, Allosteric and ATP-Competitive Inhibitors
17. Discovery of Stereospecific PARP-1 Inhibitor Isoindolinone NMS-P515
18. A benchmarking of pipelines for detecting ncRNAs from RNA-Seq data.
19. Abstract 4843: NMS-P293, a PARP-1 selective inhibitor with no trapping activity and high CNS penetration, possesses potent in vivo efficacy and represents a novel therapeutic option for brain localized metastases and glioblastoma
20. Abstract 4785: NMS-E668, a highly potent orally available RET inhibitor with selectivity towards VEGFR2 and demonstrated antitumor efficacy in multiple RET-driven cancer models
21. Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury
22. Tyrosine 319, a Newly Identified Phosphorylation Site of ZAP-70, Plays a Critical Role in T Cell Antigen Receptor Signaling
23. Establishment and genomic characterization of the new chordoma cell line Chor-IN-1
24. Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient
25. KAOS: a new automated computational method for the identification of overexpressed genes
26. Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds
27. Abstract 1223: NMS-P293, a novel potent and selective PARP-1 inhibitor with high antitumor efficacy and tolerability
28. Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
29. PoInTree: A Polar and Interactive Phylogenetic Tree
30. Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer
31. Abstract A149: NMS-P945, a highly active payload for antibody drug conjugates generation
32. Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
33. Abstract 1638: Preclinical characterization of the novel TTK kinase inhibitor S81694 for the treatment of triple negative breast cancer
34. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma
35. Abstract 4539: NMS-P862, a novel orally available selective small molecule Cdc7 inhibitor with antitumor efficacy in breast cancer
36. Abstract 822: Thienoindoles, a novel class of DNA minor groove alkylating agents highly suited for the generation of novel antibody drug conjugates (ADCs)
37. NMS-E973, a Novel Synthetic Inhibitor of Hsp90 with Activity against Multiple Models of Drug Resistance to Targeted Agents, Including Intracranial Metastases
38. Abstract 2091: Identification of a highly potent, selective and orally available RET inhibitor with antitumor efficacy in RET-dependent tumor models.
39. Abstract 2092: The ALK inhibitor NMS-E628 also potently inhibits ROS1 and induces tumor regression in ROS-driven models .
40. NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies
41. Abstract 3754: Characterization of NMS-P285, a new highly selective and potent BRAF inhibitor
42. Abstract 1775: Characterization of new highly selective and potent PARP-1 inhibitors
43. Abstract 2940: Identification of potent VCP/p97/CDC48 inhibitors with distinct biochemical mechanisms including a reversible, allosteric inhibitor that activates the unfolded protein response, induce autophagy and cancer cell death
44. Transcriptional analysis of the Aurora inhibitor Danusertib leading to biomarker identification in TP53 wild type cells
45. Abstract A232: In vitro and in vivo activity of NMS-E628 against ALK mutations resistant to Xalkori.
46. Abstract B230: NMS-P948, a potent dual FLT3/KIT inhibitor, also active on secondary resistance mutations.
47. Abstract B241: Targeting the mitotic checkpoint with NMS-P153, a novel MPS1 kinase inhibitor.
48. Targeting the Mitotic Checkpoint for Cancer Therapy with NMS-P715, an Inhibitor of MPS1 Kinase
49. Identification of small molecules enhancing autophagic function from drug network analysis
50. Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.